Simple Summary In hematologic cancers, Minimal Residual Disease (MRD) monitoring,
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …

PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal
residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia …

Purpose: This study was undertaken to determine cancer survival and describe the spectrum
of cancers diagnosed among French adolescent and young adult (AYA) population …

Measurable/minimal residual disease (MRD) status has been suggested as a powerful
indicator of clinical‐outcome in T‐cell lymphoblastic leukemia/lymphoma (T‐ALL). Multicolor …

While outcome for pediatric T lymphoblastic lymphoma (T-LL) has improved with acute
leukemia-type therapy, survival after relapse remains rare. Few prognostic markers have …

Two quantitative PCR (qPCR)–based methods, for clonal immunoglobulin or T-cell receptor
gene (Ig/TCR) rearrangements and for fusion transcripts, are widely used for the …

Treating refractory pediatric acute lymphoblastic leukemia (ALL) remains a challenge
despite impressive remission rates (> 90%) achieved in the last decade. The use of …

Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of
Minimal Residual Disease (MRD) has progressively become a keystone in the clinical …

The IKZF1 gene encodes the transcription factor IKAROS, a master regulator of lymphocyte
differentiation. IKZF1 is commonly deleted in acute lymphoblastic leukaemia (ALL) …

A mis directores de tesis, porque con su consejo y sabiduría, ha sido un camino de rosas.
Gracias a Miguel Sanz, por su estímulo constante, disponibilidad desinteresada y …